Stratos Wealth Partners, Ltd. Phathom Pharmaceuticals, Inc. Transaction History
Stratos Wealth Partners, Ltd.
- $8.26 Billion
- Q4 2025
A detailed history of Stratos Wealth Partners, Ltd. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Stratos Wealth Partners, Ltd. holds 50,300 shares of PHAT stock, worth $738,907. This represents 0.01% of its overall portfolio holdings.
Number of Shares
50,300Holding current value
$738,907% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
153Shares Held
65.4MCall Options Held
1.15MPut Options Held
170K-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$183 Million6.03% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$110 Million12.93% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...